Literature DB >> 26324153

If not now, when? Prescription of evidence-based medical therapy prior to hospital discharge increases utilization at 6 months in patients with symptomatic peripheral artery disease.

Brian M Renard1, Milan Seth2, David Share3, Herb D Aronow4, Eugene W Laveroni5, Michele De Gregorio6, Sachinder S Hans7, Peter K Henke8, Hitinder S Gurm2, P Michael Grossman9.   

Abstract

We evaluated the impact of the prescription of evidence-based medical therapy (EBMT) including aspirin (ASA), beta-blockers (BB), ACE-inhibitors or angiotensin receptor blockade (ACE/ARB), and statins prior to discharge after peripheral vascular intervention (PVI) on long-term medication utilization in a large multi-specialty, multicenter quality improvement collaborative. Among patients undergoing coronary revascularization, use of the component medications of EBMT at hospital discharge is a major predictor of long-term utilization. Predictors of EBMT use after PVI are largely unknown. A total of 10,169 patients undergoing PVI between 1 January 2008 and 31 December 2011 were included. Post-PVI discharge and 6-month medication utilization in patients without contra-indications to ASA, BB, ACE/ARB, and statins were compared. ASA was prescribed at discharge to 9345 (92%) patients, BB to 7012 (69%), ACE/ARB to 6424 (63%), and statins to 8342 (82%), and all four component drugs of EBMT in 3953 (39%). Compared with patients not discharged on the appropriate medications, post-procedural use was associated (all p<0.001) with reported 6-month use: ASA (84.5% vs 39.2%), BB (82.5% vs 11.1%), ACE/ARB (78.2% vs 11.8%), statins (84.6% vs 21.8%). Multivariable analysis revealed that prescription of EBMT at the time of discharge remained strongly associated with use at 6 months for each of the individual component drugs as well as for the combination of all four EBMT medications. In conclusion, prescription of the component medications of EBMT at the time of PVI is associated with excellent utilization at 6 months, while failure to prescribe EBMT at discharge is associated with low use of these medications 6 months later. These data suggest that the time of a PVI is a therapeutic window in which to prescribe EBMT in this high-risk cohort and represents an opportunity for quality improvement.
© The Author(s) 2015.

Entities:  

Keywords:  evidence-based medical therapy; peripheral artery disease; peripheral vascular intervention; quality improvement

Mesh:

Substances:

Year:  2015        PMID: 26324153     DOI: 10.1177/1358863X15599249

Source DB:  PubMed          Journal:  Vasc Med        ISSN: 1358-863X            Impact factor:   3.239


  3 in total

1.  Heterogeneity of Ankle-Brachial Indices in Patients Undergoing Revascularization for Critical Limb Ischemia.

Authors:  Devraj Sukul; Scott F Grey; Peter K Henke; Hitinder S Gurm; P Michael Grossman
Journal:  JACC Cardiovasc Interv       Date:  2017-11-27       Impact factor: 11.195

2.  Racial and Gender Disparity in Achieving Optimal Medical Therapy for Inpatients with Peripheral Artery Disease.

Authors:  Leah Gober; Allen Bui; Jean Marie Ruddy
Journal:  Ann Vasc Med Res       Date:  2020-07-15

3.  Role of Renin-Angiotensin-Aldosterone System Inhibition in Patients Undergoing Carotid Revascularization.

Authors:  Nadin Elsayed; Jonathan Unkart; Mohammad Abdelgawwad; Isaac Naazie; Peter F Lawrence; Mahmoud B Malas
Journal:  J Am Heart Assoc       Date:  2022-08-24       Impact factor: 6.106

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.